Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340610 · ClinicalTrials.gov registry record · Phase 4
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
A Phase 4 study of Diabetic Macular Edema, sponsored by Southeast Retina Center, Georgia.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03340610 is a Phase 4 study of Diabetic Macular Edema that has completed, run by Southeast Retina Center, Georgia. The registered enrollment target is 30 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03340610, a Phase 4 study of Diabetic Macular Edema, has completed, sponsored by Southeast Retina Center, Georgia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
Conditions Studied
Interventions
- DRUG Alflibercept
Study Locations (1)
Georgia
- Southeast Retina Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03340610
The ClinicalTrials.gov registry entry for NCT03340610 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The listed sponsor is Southeast Retina Center, Georgia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Alflibercept is the first listed.
NCT03340610 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03340610 about?
NCT03340610 is a clinical study titled "IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab". This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
What is the current status of trial NCT03340610?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2015-06. Estimated completion is 2018-12-12.
What conditions does trial NCT03340610 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT03340610?
The interventions under investigation include: Alflibercept (DRUG).
Who is sponsoring clinical trial NCT03340610?
This trial is sponsored by Southeast Retina Center, Georgia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03340610 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 4
-
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 4
-
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
ACTIVE NOT RECRUITING · Phase 4
-
Ocular Safety and Usability Study for FYB203 PFS
COMPLETED · Phase 4
-
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
COMPLETED · Phase 4
-
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.